Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Coherus Oncology, Inc. is a U.S.-based biopharmaceutical company focused on the development and commercialization of immuno-oncology therapies for cancer. The company operates within the oncology and biopharmaceuticals industry, with a strategic emphasis on antibody-based therapeutics that address significant unmet needs in solid tumors. Its primary revenue driver is its oncology portfolio, particularly its immune checkpoint inhibitor assets, with commercial activities centered on the U.S. oncology market.
The company was originally founded in 2010 as Coherus BioSciences, Inc., with an initial focus on biosimilar development. Over time, Coherus evolved its strategy, and by 2023–2024 undertook a major transformation to become a pure-play oncology company, rebranding as Coherus Oncology, Inc. This shift followed regulatory approval and commercialization of its lead oncology asset and the divestiture or wind-down of most biosimilar-related activities. The company’s positioning centers on leveraging late-stage clinical assets and commercial execution in narrowly defined cancer indications.
Business Operations
Coherus Oncology’s operations are organized around a single primary business segment: Oncology Therapeutics, which encompasses research, development, regulatory approval, and commercialization of cancer immunotherapies. The company generates revenue primarily from product sales of its FDA-approved oncology drug and from collaboration-related activities tied to its licensed assets. Domestic operations in the United States represent the core of its commercial and regulatory activities.
The company’s flagship product is LOQTORZI® (toripalimab-tpzi), a programmed death receptor-1 (PD‑1) monoclonal antibody approved by the U.S. Food and Drug Administration for the treatment of recurrent or metastatic nasopharyngeal carcinoma. LOQTORZI® is licensed from Shanghai Junshi Biosciences Co., Ltd., which remains responsible for development and commercialization outside certain licensed territories. Beyond its lead product, Coherus Oncology controls a pipeline of earlier-stage immuno-oncology assets, though data on the scope and timing of these programs is limited based on available public disclosures.
Strategic Position & Investments
Strategically, Coherus Oncology is focused on becoming a sustainable, revenue-generating oncology company by maximizing the commercial potential of LOQTORZI® while advancing a targeted pipeline of differentiated immunotherapies. Growth initiatives emphasize label expansion opportunities, physician adoption in specialty oncology settings, and operational efficiency following the company’s restructuring away from biosimilars.
The company’s most significant strategic investment is its long-term licensing and collaboration agreement with Shanghai Junshi Biosciences Co., Ltd., which provides Coherus with U.S. and certain other territorial rights to toripalimab. Coherus has publicly disclosed efforts to reduce operating complexity and strengthen its balance sheet through asset divestitures related to its former biosimilar business; however, specific financial terms and the full scope of retained or exited assets are not consistently detailed across public sources. Data inconclusive based on available public sources regarding additional late-stage acquisitions or equity investments.
Geographic Footprint
Coherus Oncology is headquartered in the United States, with its principal executive offices in California. The company’s commercial focus is primarily on North America, where it conducts sales, marketing, and medical affairs activities related to its approved oncology product. Research and development oversight and regulatory operations are also U.S.-based.
Internationally, Coherus Oncology’s footprint is largely indirect. Its global presence is supported through its strategic relationship with China-based partner Shanghai Junshi Biosciences Co., Ltd., which conducts development, manufacturing, and commercialization activities for toripalimab outside Coherus-licensed territories. As a result, the company maintains international influence through partnerships rather than through owned subsidiaries or standalone foreign operations.
Leadership & Governance
Coherus Oncology is led by an executive team with experience in biologics development, regulatory approval, and commercial execution. Leadership has emphasized strategic focus, capital discipline, and transitioning the company from a diversified biosimilars model to a streamlined oncology enterprise centered on fewer, higher-impact assets.
Key members of the leadership team include:
- Denny Lanfear – President and Chief Executive Officer
- Lenny Mack – Chief Financial Officer
- Sandeep Athalye, MD – Chief Medical Officer
- Paul Reider – Chief Commercial Officer
The board and management team oversee corporate governance, strategic planning, and compliance with U.S. public company requirements, with strategic priorities aligned toward oncology specialization and long-term value creation.